, Tracking Stock Market Picks
Enter Symbol:
Rating: IPXL
Neutral $30

Impax Laboratories, Inc. (NASDAQ: IPXL) reiterated to Neutral with price target $30 by UBS

Wednesday,  Nov 5, 2014  2:25 PM ET by Dave Ficere

UBS reiterated Impax Laboratories, Inc. (NASDAQ: IPXL) to Neutral with price target $30. Previously UBS rated Neutral
with price target $17 Impax Laboratories, Inc. (NASDAQ: IPXL) on 03/07/2013, when the stock price was $15.68. Since then, Impax Laboratories, Inc.'s stock price has gained 87% as of 11/05/2014's recent price of $29.32.

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic pharmaceuticals market, the Company focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system (CNS), disorders. Its brand-name product portfolio consists of development-stage projects to which it is applying its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceutical Division (Impax Division).

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy